Hyundai Bioscience Co., Ltd. (KOSDAQ:048410)

Market Cap	1.41T +171.3%
Revenue (ttm)	1.96B -87.6%
Net Income	-21.96B
EPS	-183.47
Shares Out	96.04M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,925,834
Average Volume	6,664,196
Open	15,240
Previous Close	15,240
Day's Range	14,480 - 15,400
52-Week Range	4,325 - 21,500
Beta	1.03
RSI	51.58
Earnings Date	Mar 25, 2026

About Hyundai Bioscience

Hyundai Bioscience Co., Ltd. operates as a biotechnology company. The company provides Vitabrid C12, a vitamin C product that delivers active vitamin C into the skin. It develops Polytaxel, a drug for pancreatic cancer and solid tumors; and CP-COV03 drug for Covid 19. The company was founded in 2000 and is based in Seoul, South Korea.

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 2000
• Employees: 69
• Stock Exchange: KOSDAQ
• Ticker Symbol: 048410

Financial Performance

In 2024, Hyundai Bioscience's revenue was 15.05 billion, an increase of 58.73% compared to the previous year's 9.48 billion. Losses were -6.93 billion, -52.21% less than in 2023.